Multidisciplinary Journal of Science and Technology

CLINICAL DYNAMICS OF HEMOSTATIC SYSTEM PARAMETERS AND THE ROLE OF BIOMARKERS IN PATIENTS WITH IMMUNE MICROTHROMBOVASCULITIS UNDER ANTICOAGULANT THERAPY

Z.Ch. Kurbanova

1 Scientific Supervisor: Doctor of Science, Associate Professor Tashkent State Medical University, Tashkent, Uzbekistan

Sayfuddinova Z.A

2 PhD, Docent Tashkent State Medical University, Tashkent, Uzbekistan

.A. Begmatova3

Laboratory Work of a Master's Student Tashkent State Medical University, Tashkent, Uzbekistan

Keywords: Immune microthrombovasculitis, anticoagulant therapy, hemostatic parameters, D-dimer, fibrinogen, von Willebrand factor, C-reactive protein.

---

Abstract

Immune microthrombovasculitis (IMTV) is a rare disorder characterized by immune-mediated microvascular thrombosis, often requiring anticoagulant therapy to mitigate thrombotic complications. This prospective study investigates the dynamics of hemostatic system parameters (D-dimer, fibrinogen, prothrombin time [PT], activated partial thromboplastin time [APTT]) and biomarkers (von Willebrand factor [vWF], C-reactive protein [CRP]) in 40 patients with IMTV over a 12-month period. Patients received either warfarin or direct oral anticoagulants (DOACs). Significant reductions in D-dimer levels (from 1.3 µg/mL to 0.5 µg/mL, p<0.01) and stabilization of APTT were observed in 85% of DOAC-treated patients. Fibrinogen levels remained elevated in 55% of patients, correlating with CRP (r=0.68, p<0.01). Elevated vWF levels at baseline (185 IU/dL) decreased modestly (145 IU/dL, p=0.04), reflecting partial endothelial recovery. Persistent vWF elevation was associated with a 20% incidence of recurrent thrombotic events. These findings underscore the utility of hemostatic parameters and biomarkers in monitoring therapy efficacy and predicting outcomes, advocating for personalized treatment strategies in IMTV.

---

References

1. Cervera R. et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients //Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. – 2002. – Т. 46. – №. 4. – С. 1019-1027.

2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x

3. Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med. 2017;377(12):1177-1187. doi:10.1056/NEJMra1700365

4. Lippi G, Favaloro EJ. D-dimer measurement and laboratory feedback. J Thromb Haemost. 2017;15(7):1453-1456. doi:10.1111/jth.13706

5. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008;117(11):1449-1459. doi:10.1161/CIRCULATIONAHA.107.722827

6. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026

7. Pagnoux C, Cohen P, Guillevin L. Vasculitides: classification, clinical features, and management. Curr Opin Rheumatol. 2010;22(1):1-8. doi:10.1097/BOR.0b013e328333d7e3

8. Sonneveld MA, de Maat MP, Leebeek FW. von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev. 2014;28(4):167-178. doi:10.1016/j.blre.2014.04.003

9. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi:10.1002/art.37715

10. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405

11. Favaloro EJ, Lippi G. Laboratory testing in the era of direct oral anticoagulants: a practical guide. Semin Thromb Hemost. 2015;41(3):277-291. doi:10.1055/s-0035-1546827

12. Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. J Am Coll Cardiol. 2017;70(19):2411-2420. doi:10.1016/j.jacc.2017.09.024

13. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38(2 Suppl):S26-S34. doi:10.1097/CCM.0b013e3181c98d21

14. Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41(1):206-232. doi:10.1007/s11239-015-1310-7

15. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4(6):1186-1193. doi:10.1111/j.1538-7836.2006.01949.x

16. Ruggeri ZM. von Willebrand factor: looking back and looking forward. Thromb Haemost. 2007;98(1):55-62. doi:10.1160/TH07-01-0010

17. Tripodi A, Mannucci PM. Laboratory monitoring of anticoagulation: where do we stand? Semin Thromb Hemost. 2009;35(1):34-41. doi:10.1055/s-0029-1214146

18. Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010;121(13):1523-1532. doi:10.1161/CIRCULATIONAHA.109.853119

19. Korte W, Riesen WF. Fibrinogen and cardiovascular risk. Semin Thromb Hemost. 2000;26(3):323-327. doi:10.1055/s-2000-8467

20. Franchini M, Mannucci PM. von Willebrand factor: another janus-faced hemostasis protein. Semin Thromb Hemost. 2008;34(7):663-669. doi:10.1055/s-0028-1103367

21. Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood. 2013;122(23):3735-3740. doi:10.1182/blood-2013-06-498303